Local view for "http://purl.org/linkedpolitics/eu/plenary/2009-01-13-Speech-2-381"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2009-01-13"^^xsd:date2
dcterms:Is Part Of	lp_eu:Pharmaceutical products package (debate)2
dcterms:Language	"sk"^^xsd:language2
lpv:document identification number	"en.20090113.29.2-381"2
lpv:hasSubsequent	lp_eu:2009-01-13-Speech-2-3822
lpv:speaker	lp:Irena Belohorská2
lpv:spokenAs	member; Conference of Presidents (2007-01-15--2009-07-13)3,3 member; Delegation for relations with the countries of Central America (2007-03-14--2009-07-13)3,3 substitute; AFET (2007-11-06--2009-07-13)3,3 member; DROI (2007-01-31--2009-07-13)3,3 vice-chair; Delegation to the Euro-Latin American Parliamentary Assembly (2007-10-24--2009-07-13)3,3 member; ENVI (2007-01-31--2009-07-13)3,3 unknown; Hnutie za demokratické Slovensko (2004-07-20--2009-07-13)3,3 member; NA (2004-07-20--2009-07-13)3,3
lpv:translated text	"Many of us will probably talk about healthcare subsidiarity in connection with the pharmaceutical package. Nevertheless, the situation on the pharmaceutical market indicates that, for Europe to be competitive in research and development, as well as in the distribution and sale of new medicines, closer cooperation or improved cooperation between the Member States is required in this field. Patients need to be better informed about medicines and of course about their unwanted side effects, so that they can participate in treatment more effectively. Due to limited funding for pharmaceutical research and development in Europe, the European pharmaceutical industry is unable to compete with America, Japan or Canada. That is why medicine prices have been rising disproportionately on European markets. We have discussed repeatedly in the European Parliament the insufficient accessibility of certain drugs, for example those for the treatment of cancer or so-called rare diseases. We place patients who are already in a difficult situation in the position of beggars who have to find sponsors in order to obtain treatment. The high price of many medicines forces the healthcare sector to seek cheaper alternatives, in other words generic medicines. Unfortunately, it is precisely these that are frequently counterfeited and often contain no active substance apart from sugar and the tablet compound. The aforementioned facts show us how important it is to exchange opinions, discuss and subsequently adopt a complete pharmaceutical package ensuring that patients are treated with high-quality and affordable medicines. In this context, I am looking forward to effective cooperation with the rapporteurs appointed for specific parts of the package in the Committee on the Environment, Public Health and Consumer Protection. I have to agree with the Commissioner that it is medicines sold via the Internet that greatly endanger the safety of pharmaceutical policy."@en1
lpv:videoURI	<go to Events_and_structure europarl>2

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph